UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044645
Receipt number R000050994
Scientific Title Safety evaluation of excessive intake of supplements for healthy adults
Date of disclosure of the study information 2022/08/20
Last modified on 2024/07/08 10:21:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety evaluation

Acronym

Safety evaluation

Scientific Title

Safety evaluation of excessive intake of supplements for healthy adults

Scientific Title:Acronym

Safety evaluation of excessive intake of supplements for healthy adults

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to evaluate the safety of excessive intake of the supplement, 5-fold quantity of recommended daily intake, for 4 weeks

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Hematologic test, Biochemical test, Urine test, Blood pressure/pulsation, Weight/body mass index, Medical Interview, before the study and at weeks 2 and 4 after using the test food. Adverse events thorough the study

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of the supplement, 5-fold quantity of recommended daily intake, for 4 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

Healthy males and females from 20 to 64 years old

Key exclusion criteria

(1) Subjects who are judged as unsuitable for the study based on the results of the lifestyle questionnaire
(2) Subjects who constantly use health foods richly containing the involvement ingredients
(3) Subjects having a disease requiring treatments or a history of serious diseases for which medication was required
(4) Subjects having possibilities for emerging allergy related to the study
(5) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination before the study
(6) Subjects who had participated in other clinical studies within one month before the study or are planned to participate in other clinical studies after informed consent for the study
(7) Subjects who intend to become pregnant or lactating during the test period
(8) Subjects judged as unsuitable for the study by the principle investigator for other reasons

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Yamato

Organization

Medical Corporation Kouwakai Kouwa Clinic

Division name

Internal medicine, Director

Zip code

170-0003

Address

6-33-17, Komagome, Toyoshima-ku, Tokyo

TEL

03-3917-8105

Email

info@kouwakai.jp


Public contact

Name of contact person

1st name Kei
Middle name
Last name Yasui

Organization

EP Mediate Co., Ltd.

Division name

Development Business Headquarters, TTC Center, Trial Planning Department

Zip code

162-0822

Address

Tsuruya Bldg., 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo

TEL

03-5657-4983

Homepage URL


Email

yasui475@eps.co.jp


Sponsor or person

Institute

EP Mediate Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Greenyn Biotechnology Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Station Clinic Research Ethics Committee

Address

3-12-8, Takaban, Meguroku, Tokyo

Tel

03-6452-2712

Email

saito876@eps.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 05 Month 27 Day

Date of IRB

2021 Year 05 Month 27 Day

Anticipated trial start date

2021 Year 06 Month 25 Day

Last follow-up date

2021 Year 08 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 06 Month 24 Day

Last modified on

2024 Year 07 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050994